A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Cabozantinib (Primary)
- Indications Cholangiocarcinoma
- Focus Biomarker; Therapeutic Use
- 13 Feb 2017 Results published in the Cancer journal.
- 22 Sep 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov record.
- 02 Jun 2015 Interim results(n=19) of biomarker endpoints are presented at the 51st Annual Meeting of the American Society of Clinical Oncology.